HaroldJohnBursteinMD

Oncology • Boston, MA

Breast Cancer, Hematologic Oncology

Associate Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Burstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Burstein's full profile

Already have an account?

Office
44 Binney St
# Dana
Boston, MA 02115
Phone+1 617-632-2624

Fax+1 617-632-1930

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1999
Massachusetts General HospitalResidency, Internal Medicine, 1994 - 1996
Harvard Medical SchoolClass of 1994

Certifications & Licensure

FL State Medical License 2022 - Present
RI State Medical License 2022 - 2026
CT State Medical License 2022 - 2025
MA State Medical License 1996 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Boston Magazine Castle Connolly, 2008, 2010-2013
Fellow (FASCO) American Society of Clinical Oncologists, 2012
Super Doctor SuperDoctors.com
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2000 Mar 01
Completed
Phase 2
Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2001 Mar 01
Completed
Phase 2
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer Start of enrollment: 2001 Oct 01
Completed
Phase 1, Phase 2
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer Start of enrollment: 2003 Jul 01
Completed
Phase 2
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer Start of enrollment: 2005 Jun 01
Completed
Not Applicable
Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer Start of enrollment: 1999 Mar 01
Completed
Phase 2
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer Start of enrollment: 2001 Aug 01
Completed
Phase 3
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer Start of enrollment: 2003 Jul 01
Completed
Phase 2
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer Start of enrollment: 2006 Mar 01
Completed
Not Applicable
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Start of enrollment: 2006 Sep 15
Completed
Phase 3
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer Start of enrollment: 2007 Aug 01
Completed
Phase 3
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 May 15
Active, not recruiting
Phase 3
Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer Start of enrollment: 2008 May 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

26 citations
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification.
D Trapani, M A Franzoi, H J Burstein, L A Carey, S Delaloge
Annals of Oncology. 2022-07-01
2508 citations
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer...
A. Goldhirsch, E P Winer, A S Coates, R. D. Gelber, M Piccart-Gebhart
Annals of Oncology. 2013-09-01
587 citations
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
Harold J. Burstein, Ann Alexis Prestrud, Jerome Seidenfeld, Holly Anderson, Thomas A. Buchholz
Journal of Clinical Oncology. 2010-08-10

Journal Articles

Adjuvant Capecitabine in Triple-Negative Breast Cancer
Harold Burstein, MD, JAMA
Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer
Aminah Jatoi, Antonio C Wolff, Harvey Jay Cohen, Rachel A Freedman, Gustav Magrinat, Julie Gralow, Gretchen Kimmick, Heidi D Klepin, Harold Burstein, Hyman Muss, Jeann..., Journal of the American Geriatrics Society

Lectures

Genomic Profiling in ER-Positive Breast Cancer, From MINDACT to TAILORx
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Breast Cancer, New Horizons, Current Controversies
Harvard Medical School, Boston, Massachusetts - 7/11/2013
The New York Metropolitan Breast Cancer Group 40th Annual Symposium: Breast Cancer 2013
The New York Academy of Medicine, New York, New York - 2/2/2013
Breast Cancer, New Horizons, Current Controversies
Harvard Medical School, Boston, Massachusetts - 7/12/2012
18th Annual Network of Oncology Clinicians & Researchers (NOCR) Meeting
Imedex, Las Vegas, Nevada - 2/9/2012
Join now to see all

Press Mentions

Small Benefit, Persistent Toxic Risk with Adjuvant Anthracycline in Breast CancerNovember 19th, 2024
Epirubicin plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients with TOP2A Normal Early Breast Cancer Final Results from the DBCG 07-READ TrialNovember 12th, 2024
FDA Panel Backs Cryoablation in Early Breast Cancer as Alternative to SurgeryNovember 8th, 2024
Join now to see all